Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL-Reference-Cited by-同舟云学术

Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL

Published:2016-09-27 Issue:1 Volume:470 Page:5-20
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Deans Zandra C, ,Costa Jose Luis,Cree Ian,Dequeker Els,Edsjö Anders,Henderson Shirley,Hummel Michael,Ligtenberg Marjolijn JL,Loddo Marco,Machado Jose Carlos,Marchetti Antonio,Marquis Katherine,Mason Joanne,Normanno Nicola,Rouleau Etienne,Schuuring Ed,Snelson Keeda-Marie,Thunnissen Erik,Tops Bastiaan,Williams Gareth,van Krieken Han,Hall Jacqueline A

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00428-016-2025-7.pdf

Reference49 articles.

1. Jesinghaus M, Pfarr N, Endris V, Kloor M, Volckmar AL, Brandt R, Herpel E, Muckenhuber A, Lasitschka F, Schirmacher P, Penzel R, Weichert W, Stenzinger A (2016) Genotyping of colorectal cancer for cancer precision medicine: results from the IPH Center for Molecular Pathology. Genes Chromosomes Cancer 55(6):505–521. doi: 10.1002/gcc.22352

2. Andre FE, Mardis SM, Soria JC, Siu LL, Swanton C (2014) Prioritizing targets for precision cancer medicine. Ann Oncol 25(12):2295–2303. doi: 10.1093/annonc/mdu478

3. Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16(13):1324–1334. doi: 10.1016/S1470-2045(15)00188-6

4. Tops BB, Normanno N, Kurth H, Amato E, Mafficini A, Rieber N, Le Corre D, Rachiglio AM, Reiman A, Sheils O, Noppen C, Lacroix L, Cree IA, Scarpa A, Ligtenberg MJ, Laurent-Puig P (2015) Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the onconetwork consortium. BMC Cancer 15. doi: 10.1186/s12885-015-1015-5

5. Fisher KE, Zhang L, Wang J, Smith GH, Newman S, Schneider TM, Pillai RN, Kudchadkar RR, Owonikoko TK, Ramalingam SS, Lawson DH, Delman KA, El-Rayes BF, Wilson MM, Sullivan HC, Morrison AS, Balci S, Adsay NV, Gal AA, Sica GL, Saxe DF, Mann KP, Hill CE, Khuri FR, Rossi MR (2016) Clinical validation and implementation of a targeted next-generation sequencing assay to detect somatic variants in non-small cell lung, melanoma, and gastrointestinal malignancies. J Mol Diagn 18(2):299–315. doi: 10.1016/j.jmoldx.2015.11.006

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the “MOZART” prospective observational study;The Oncologist;2024-08-23

2. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer;International Journal of Molecular Sciences;2024-07-19

3. Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer;British Journal of Cancer;2024-05-15

4. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries;The Lancet Regional Health - Europe;2024-03

5. Next-Generation Sequencing-Based Evaluation of the Actionable Mutational Landscape in Solid Tumors: the “MOZART” Prospective Observational Study;2024-02-15